R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma
NCT ID: NCT00135499
Last Updated: 2018-08-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
138 participants
INTERVENTIONAL
2001-10-16
2010-04-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1
NCT00140595
ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma
NCT00144807
ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma
NCT00140660
ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma
NCT00169130
GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma
NCT01659099
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) was considered as the standard treatment in this population. Nevertheless, this treatment is associated with some toxic events in elderly patients and it did does not succeed to increase the 3-year survival rate above 40%.
Two trials in patients above 60 years with DLCL cases were conducted by the GELA in the aim to improve the results of CHOP.
Protocol LNH 93-5 : The primary objective of this study was to compare CHOP to ACVBP in patients aged from 61 to 69 years with aggressive lymphoma and at least one adverse prognostic factor according to the International Prognostic Index.
Unlike the CHOP regimen, the ACVBP regimen includes a more intensive induction followed by a sequential consolidation with drugs different from those used during the induction phase, and includes a prevention of neuromeningeal relapses.
Out of 708 patients included in this study, the results have shown that:
* Complete response rate was the same in the two arms.
* Event free survival was significantly better in the ACVBP arm than the CHOP arm ( 5-year survival rate : 39% versus 29%, p=0.005).
* Overall survival was significantly better in the ACVBP arm than in the CHOP arm (the 5-year survival rate : 46% versus 38%, p=0.036).
* The ACVBP regimen was more toxic than the CHOP regimen, particularly in elderly patients (\> 65 years) and in patients with a low performance status.
* Prevention of neuromeningeal relapses was necessary for these patients.
Protocol LNH 98-5, the objective of this study was to compare the association CHOP + rituximab (R-CHOP) to the CHOP regimen alone in elderly patients with non previously treated diffuse large B-cell lymphoma.
Long-term results based on data from 399 patients, with a median follow-up of 5 years were as follows :
* Complete response rate was better in the R-CHOP arm than in the CHOP arm (76% versus 61%, p\<0.005).
* Significant prolongation of event-free survival (p\<0.0002) and overall survival (p\<0.0073) in the R-CHOP arm.
* No significant difference between the two arms in terms of toxicity. R-CHOP is now considered worldwide as the standard combination for these patients.
These conclusions invited us to propose a randomized trial comparing ACVBP + rituximab to CHOP + rituximab. The study population is limited to patients aged from 60 to 65 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
R-ACVBP
Rituximab, Doxorubicin, Cyclophosphamide, Vindesine, Bleomycin, Prednisone
Rituximab
375 mg/m², D1, 4 cycles
Doxorubicin
75 mg/m², D1, 4 cycles
Cyclophosphamide
1200 mg/m², D1, 4 cycles
Vindesine
2 mg/m², D1, D5, 4 cycles
Bleomycin
10 mg, D1, D5, 4 cycles
Prednisone
60 mg, D1-D5, 4 cycles
R-CHOP
Rituximab, Doxorubicin, Cyclophosphamide, Vincristine, Prednisone
Rituximab
375 mg/m², D1, 4 cycles
Prednisone
40 mg, D1-D5, 4 cycles
Doxorubicin
50 mg/m², D1, 4 cycles
Cyclophosphamide
750 mg/m², D1, 4 cycles
Vincristine
1.4 mg/m², D1, 4 cycles
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rituximab
375 mg/m², D1, 4 cycles
Doxorubicin
75 mg/m², D1, 4 cycles
Cyclophosphamide
1200 mg/m², D1, 4 cycles
Vindesine
2 mg/m², D1, D5, 4 cycles
Bleomycin
10 mg, D1, D5, 4 cycles
Prednisone
60 mg, D1-D5, 4 cycles
Prednisone
40 mg, D1-D5, 4 cycles
Doxorubicin
50 mg/m², D1, 4 cycles
Cyclophosphamide
750 mg/m², D1, 4 cycles
Vincristine
1.4 mg/m², D1, 4 cycles
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged from 60 to 65 years.
* Not previously treated.
* Ann Arbor stage II, III, IV.
* ECOG performance status 0 to 2.
* Minimum life expectancy of 3 months.
* Negative HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV) serologies test 4 weeks (except after vaccination).
* Having previously signed a written informed consent.
Exclusion Criteria
* Any history of treated or non-treated indolent lymphoma. However, patients not previously diagnosed and having a diffuse large B-cell lymphoma with some small cell infiltration in bone marrow or lymph node may be included.
* Central nervous system or meningeal involvement by lymphoma.
* Contra-indication to any drug contained in the chemotherapy regimens.
* Any serious active disease (according to the investigator's decision).
* Poor renal function (creatinine level\>150micromol/l), poor hepatic function (total bilirubin level\>30mmol/l, transaminases\>2.5 maximum normal level) unless these abnormalities are related to the lymphoma.
* Poor bone marrow reserve as defined by neutrophils\<1.5G/l or platelets\<100G/l, unless related to bone marrow infiltration.
* Any history of cancer during the last 5 years with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma.
* Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy and during the study.
* Adult patient under tutelage.
60 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondation ARC
OTHER
Lymphoma Study Association
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Herve Tilly, MD
Role: PRINCIPAL_INVESTIGATOR
Lymphoma Study Association
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Groupe d'Etude des Lymphomes de l'adulte
Yvoir, , Belgium
Hôpital Henri Mondor
Créteil, , France
Hôpital Saint Louis
Paris, , France
Service d'Hématologie - Centre Hospitalier Lyon-Sud
Pierre-Bénite, , France
Centre Hospitalier Robert Debré
Reims, , France
Centre Henri Becquerel
Rouen, , France
Institut Gustave Roussy
Villejuif, , France
Schweirische Arbeitsgruppe fur klinische Krebsforschung
Lausanne, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, Attal M, Fillet G, Guettier C, Molina TJ, Gisselbrecht C, Reyes F; Groupe d'Etude des Lymphomes de l'Adulte. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003 Dec 15;102(13):4284-9. doi: 10.1182/blood-2003-02-0542. Epub 2003 Aug 14.
Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002 Jan 24;346(4):235-42. doi: 10.1056/NEJMoa011795.
Ghesquieres H, Larrabee BR, Haioun C, Link BK, Verney A, Slager SL, Ketterer N, Ansell SM, Delarue R, Maurer MJ, Fitoussi O, Habermann TM, Peyrade F, Dogan A, Molina TJ, Novak AJ, Tilly H, Cerhan JR, Salles G. FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts. Hematol Oncol. 2017 Dec;35(4):447-455. doi: 10.1002/hon.2305. Epub 2016 Jun 10.
Copie-Bergman C, Cuilliere-Dartigues P, Baia M, Briere J, Delarue R, Canioni D, Salles G, Parrens M, Belhadj K, Fabiani B, Recher C, Petrella T, Ketterer N, Peyrade F, Haioun C, Nagel I, Siebert R, Jardin F, Leroy K, Jais JP, Tilly H, Molina TJ, Gaulard P. MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. Blood. 2015 Nov 26;126(22):2466-74. doi: 10.1182/blood-2015-05-647602. Epub 2015 Sep 15.
Related Links
Access external resources that provide additional context or updates about the study.
Official site of the Groupe d'Etudes des Lymphomes de l'Adulte (In french)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LNH01-5B
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.